Drug
Piflufolastat (18F)
Piflufolastat (18F) is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
50%
Ph phase_4
1
50%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(1)
Terminated(1)
Detailed Status
Completed1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (50.0%)
Phase 41 (50.0%)
Trials by Status
completed150%
withdrawn150%
Recent Activity
0 active trials
Showing 2 of 2
withdrawnphase_1
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
NCT06881823
completedphase_4
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
NCT06604442
Clinical Trials (2)
Showing 2 of 2 trials
NCT06881823Phase 1
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
NCT06604442Phase 4
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2